Canada Pension Plan Investment Board Purchases Shares of 132,600 Halozyme Therapeutics, Inc. $HALO

Key Points

• Canada Pension Plan Investment Board acquired 132,600 Halozyme shares worth approximately $10.4 million, while institutional investors collectively owned 97.79% of the company.
• Halozyme reported quarterly EPS of $2.28, exceeding the $1.79 consensus estimate, and revenue of $481 million, up 47.7% year over year. The company set fiscal 2026 EPS guidance at $8.65–$9.00.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $91.20. However, insiders sold 64,103 shares worth about $5.2 million over the past 90 days.

Canada Pension Plan Investment Board acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,600 shares of the biopharmaceutical company's stock, valued at approximately $10,379,000. Canada Pension Plan Investment Board owned about 0.12% of Halozyme Therapeutics at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of HALO. Measured Wealth Private Client Group LLC boosted its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares in the last quarter. Abel Hall LLC grew its position in Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock worth $216,000 after acquiring an additional 129 shares during the last quarter. StoneX Group Inc. increased its holdings in Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock valued at $246,000 after purchasing an additional 132 shares in the last quarter. Twin Capital Management Inc. increased its holdings in Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 161 shares in the last quarter. Finally, Coldstream Capital Management Inc. raised its position in Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock valued at $654,000 after purchasing an additional 165 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock worth $5,226,496 over the last 90 days. Insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HALO shares. Citizens Jmp boosted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research note on Friday, August 7th. Morgan Stanley lowered their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. UBS Group reiterated a "buy" rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Weiss Ratings lowered shares of Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $91.20.

Halozyme Therapeutics Stock Down 1.5%

NASDAQ:HALO opened at $105.35 on Friday. The stock's fifty day moving average price is $87.01 and its two-hundred day moving average price is $74.78. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $109.66. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $11.96 billion, a price-to-earnings ratio of 31.45, a P/E/G ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.